As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 470 Wildwood Ave, Woburn, MA 01801 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
BioForward 2022 is only one week to go! Medicilon is excited to exhibit in the conference. Medicilon European Team will be waiting at Stand 22. We are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs. We look forward to seeing you soon and wish you safe trips!
Date: Tuesday, Septemper 27, 2022 (8 AM - 6 PM) (GMT+1)
Location: England, United Kingdom
Stand: 22
BioForward is OBN's 'Roadmap for Growth' Life Sciences event, designed to provide the support, skills, know-how and industry connections required to build a commercially successful business. Now in its fourth year, the event is attended by leaders and decision makers of growing R&D companies across all therapy and technological areas, along side companies who provide critical support services to emerging companies within the life sciences ecosystem. BioForward has been specifically designed for growing life sciences R&D companies, and high-quality Service Providers who can provide the critical support and advice required to help them build a commercially sustainable business.
Agenda
About Medicilon
Fully Integrated Preclinical Drug Discovery and Development Services
Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.
At Medicilon, we are dedicated to help our clients develop their research and discovery programs from initial idea all the way through the Investigational New Drug (IND) filing phase. Our services span across medicinal chemistry, biology, API, CMC, formulation, and preclinical studies. We provide flexible business models, including stand-alone Fee for Services (FFS) and fully integrated FTE services. In addition, our facilities are GLP/GMP compliant, US-FDA, China NMPA and AAALAC accredited. All study reports can be presented in SEND format, supporting dual filing of IND applications in the US, EU, and China.
18+
18+ years of experience in new drug R&D
1710+
Active clients worldwide
2800+
Newdrug discovery scientists and service personnel
81600+
Square meters of Laboratory floor space
268
Projects successfully approved with FDA, NMPA, EMA, and TGA
Drug Discovery
❖Medicinal Chemistry
❖Biology Services
CMC Services
❖Intermediates
❖APIs
❖Pharmaceutic Formulation
Preclinical Studies
❖Pharmacodynamics
❖Pharmacokinetics
❖Drug Safety Evaluation
❖IND Filing
One-stop Integrated Services Platform
❖PROTAC Drug Discovery Research Platform
❖Antibody-Drug Conjugate(ADC) R&D Service Platform
❖Nucleic Acid Drug R&D Platform
❖Cytokine and Biomarker Detection Platform
❖Flow Cytometry Technology Platform
❖mRNA Vaccine Bioanalysis Platform
❖Pharmaceutical Research CDMO Service Platform
❖Process Department Solid Form Screening Platform
❖Inhalation drug R&D platform
❖Skin Topical Preparation R&D
❖IO Pharmacodynamic Model Evaluation Platform
❖Cellular Immunotherapies R&D platform
❖Ophthalmic drug R&D platform